IGM Biosciences
IGMS
IGMS was delisted on the 13th of August, 2025.
92 hedge funds and large institutions have $402M invested in IGM Biosciences in 2022 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 30 increasing their positions, 28 reducing their positions, and 14 closing their positions.
129% more call options, than puts
Call options by funds: $1.54M | Put options by funds: $670K
29% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 14
27% more capital invested
Capital invested by funds: $316M → $402M (+$86.4M)
3% more funds holding
Funds holding: 89 → 92 (+3)
7% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 28
2.82% less ownership
Funds ownership: 63.87% → 61.06% (-2.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$9.09M |
| 2 |
D.E. Shaw & Co
New York
|
+$1.26M |
| 3 |
Goldman Sachs
New York
|
+$1.02M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$985K |
| 5 |
State Street
Boston,
Massachusetts
|
+$700K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.18M |
| 2 |
Millennium Management
New York
|
-$6.02M |
| 3 |
Alkeon Capital Management
New York
|
-$1.46M |
| 4 |
HF
HRT Financial
New York
|
-$1.27M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$1.27M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$50K | -2,750 | Closed |
|
|
ACM
102
Aquatic Capital Management
Chicago,
Illinois
| – | -$11K | -600 | Closed |
|
|
SOW
103
State of Wyoming
Cheyenne,
Wyoming
| – | -$5K | -269 | Closed |
|
|
PFS
104
Prospera Financial Services
Dallas,
Texas
| – | -$2K | -98 | Closed |
|
|
DFCM
105
Dark Forest Capital Management
San Juan,
Puerto Rico
| – | +$40 | +2 | New |
|
|
PA
106
Parallel Advisors
San Francisco,
California
| – | +$262 | +13 | New |
|
IGMS Hedge Fund Activity: Q3 2022 in Review
92 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q3 2022, worth a combined $402M — up 27% from $316M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new IGMS positions and 14 closed out — a net gain of 4 holders — while 30 added to existing stakes and 28 trimmed.
The largest buyer was Artal Group, adding an estimated $9.09M. The largest seller was T. Rowe Price Associates, cutting an estimated $8.18M.
- 92 institutional investors held IGM Biosciences (IGMS) as of Q3 2022, up from 89 in Q2 2022.
- Funds reported $402M of IGM Biosciences stock for Q3 2022, up 27% quarter-over-quarter.
- 18 funds opened new IGM Biosciences positions in Q3 2022 and 14 closed out, a net change of +4 holders.
- The largest IGM Biosciences buyer in Q3 2022 was Artal Group, an estimated $9.09M added.
- The largest IGM Biosciences seller in Q3 2022 was T. Rowe Price Associates, an estimated $8.18M sold.
Based on aggregated 13F filings for Q3 2022.